Ann: Positive Interim Results From Clinical Trial at St Vincent's, page-17

First 17 Last

Share
Profile

Follow
fluke74

4 Posts.

1

16/12/22

16:05

Post #: 65344283
Share

Originally posted by triage: ↑

Hi fluke, bear with me while I test my logic. It is stated that EchoSolv picks up all of the true positives which is another way of saying that EchoSolv picks up all of the severe cases picked up by the doctors. But then on top of that EchoSolv also identifies another bunch of cases as also having severe cases aortic stenosis that the doctors have not picked up. Now, that extra bunch either have severe aortic stenosis and the doctors missed it or EchoSolv is identifying them as having severe AS but they actually do not have severe AS. In the latter instance then all those extra cases that EchoSolv identifies as having severe AS are false positives (aka in that extra bunch of cases EchoSolv is identifying severe AS but the patient does not actually have severe AS so EchoSolv is returning a false positive result). Does that make sense?

Anyway, perhaps I should bypass the label and just focus on the key question being how many of those extra cases that EchoSolv identifies as having severe AS actually have severe AS.

Good to see that with a good announcement the EIQ share price did not tank (as often is the case in my experience - ignore the rumour but sell the news.

Expand

Thank you Triage for the explanation. I was under the impression that EcoSolv was a decision support tool and not a diagnostic tool which was the reason for my comment. Your comments make sense

EIQ Price at posting: 20.5¢ Sentiment: None Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

There are more pages in this discussion • 1 more message in this thread...

First 17 Last

Add EIQ (ASX) to my watchlist

(20min delay)
Last 24.0¢		Change 0.000(0.00%)		Mkt cap ! $141.2M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

Buyers (Bids)

No.	Vol.	Price($)
5	120617	27.0¢

Sellers (Offers)

Price($)	Vol.	No.
24.0¢	17083	2

View Market Depth

No.	Vol.	Price($)
5	120617	0.270
3	122000	0.255
10	182100	0.250
1	175317	0.245
8	208155	0.240

Price($)	Vol.	No.
0.240	17083	2
0.245	90000	2
0.250	703130	6
0.260	208882	4
0.265	112000	3

Last trade - 16.14pm 07/10/2024 (20 minute delay)

EIQ (ASX) Chart

Day chart unavailable

Ann: Positive Interim Results From Clinical Trial at St Vincent's, page-17

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Positive Interim Results From Clinical Trial at St Vincent's, page-17

Top Stories

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News